Navigation Links
Omeros Licenses Novel Antifibrinolytic Agents
Date:1/5/2011

logical side effects. Worldwide revenues for Trasylol® (aprotinin), which was permanently withdrawn in 2008 after its use was found to be associated with increased mortality, peaked at $285 million in 2005.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery™ platform, the most advanced of which is in a Phase 3 clinical program, and one from its Addiction program. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and central nervous system disorders.

Forward-looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release and include Omeros' ability to advance an antifibrinolytic agent rapidly into the clinic and the ability of its agents to provide more effective bleeding control with fewer side effects than other antifibrinolytics. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
2. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
3. Omeros to Present at the BioCentury NewsMakers Conference
4. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
5. Omeros Successfully Unlocks Orphan GPCRs
6. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
7. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
8. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
11. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... to anti-clotting drug, CHICAGO, March 29 ... dose of a medication that prevents blood clotting,significantly ... coronary interventions (PCI), according to a multicenter study,reported ... the SCAI,Annual Scientific Sessions in Partnership with ACC ...
... ,culotte, technique better?, CHICAGO, March 29 When ... of two coronary arteries -- or a,bifurcation lesion -- ... vessels without blocking the opening to the side branch. ... on which of,two techniques produces the best long-term results ...
Cached Medicine Technology:Tailored Clopidogrel Dosing Improves PCI Outcomes 2Tailored Clopidogrel Dosing Improves PCI Outcomes 3Stenting Techniques Vie in Branchpoint Lesions 2
(Date:4/14/2014)... Doctors at Henry Ford Hospital reached a medical ... replacement using a novel way to access the heart. ... United States performing the unique procedure called transcaval valve ... blood vessels. , Northern Michigan resident Viola Waller, 80, ...
(Date:4/14/2014)... , , Penicillin, one of the scientific marvels of the ... it once won against bacterial infections. But scientists at ... new approach to restoring its combat effectiveness, even against ... the power of the penicillin family of drugs since ...
(Date:4/14/2014)... their radiation treatment decisions leaves cancer patients feeling more ... distress around the experience, researchers from the Perelman ... report in the journal Cancer . , In ... Neha Vapiwala, MD , an associate professor in the ...
(Date:4/14/2014)... Popular web information on colorectal cancer is too ... address the appropriate risks to and concerns of patients, ... , In a review of a dozen popular websites, ... cancer screening were written beyond the recommended sixth-grade reading ...
(Date:4/14/2014)... the molecule, called microRNA 135b, is a vital ,worker, ... growth of bowel cancers. , Drugs targeted at the ... mutations at once, while tests for it could identify ... , The research was carried out by an international ...
Breaking Medicine News(10 mins):Health News:Henry Ford Hospital hits new heart valve surgery milestone 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:Shared decision making during radiation therapy improves patient satisfaction 2Health News:Shared decision making during radiation therapy improves patient satisfaction 3Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3Health News:'MicroRNA' could be key target for bowel cancer treatment 2
... French . , Montreal, February 22, 2010 ... young immigrants. A new study published in the Journal ... children from multiethnic, disadvantaged, inner-city neighbourhoods are up to 3.5 ... an estimated 45,000 school-aged children immigrate to Canada with their ...
... URBANA - A University of Illinois researcher advises caution ... this country,s Latino adolescents and young adults. "When ... in a 90-minute program, the Latino students in my classes ... were right!" said Marcela Raffaelli, a U of I professor ...
... ... Boehringer Ingelheim (Canada) Ltd. , ... Toronto, Ontario, Canada (PRWEB) February 22, 2010 -- Dalton Pharma Services announces ... the agreement Dalton will continue to provide chemistry services in support of Boehringer,s pharmaceutical ...
... life, researchers say , MONDAY, Feb. 22 (HealthDay News) ... causes low energy levels and reduced quality of life, ... a new study suggests. , About 15 percent of ... late side effect of chemotherapy or radiation therapy. , ...
... ... ... ... ...
... , ... ... ... ...
Cached Medicine News:Health News:Are Latino teens sexual risk takers? It's complicated, researcher says 2Health News:Are Latino teens sexual risk takers? It's complicated, researcher says 3Health News:Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement 2Health News:Testicular Cancer Survivors May Have Hormone Deficiency 2Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 2Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 3Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 4Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 5Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 6Health News:57 Year-Old Grandmother Travels to Atacama Desert to Run First of Four Ultramarathons for Charity 2Health News:57 Year-Old Grandmother Travels to Atacama Desert to Run First of Four Ultramarathons for Charity 3Health News:57 Year-Old Grandmother Travels to Atacama Desert to Run First of Four Ultramarathons for Charity 4Health News:57 Year-Old Grandmother Travels to Atacama Desert to Run First of Four Ultramarathons for Charity 5Health News:57 Year-Old Grandmother Travels to Atacama Desert to Run First of Four Ultramarathons for Charity 6
... , , The Shortyavailable with both Impact ... our face-to-face relationship with the scientific community generates ... pipetting easier and more effective., Shorter and ... Gets you closer to the working area ...
... Powerful and Flexible Impact And Impact2 Pipettors ... volume ranges, our single channel Impact and ... of any application. Engineered with the same ... multichannel line, these pipettors are equally easy ...
... And Impact2 Pipettors , , Available ... channel Impact and Impact2 pipettors can effectively ... with the same ergonomic design and superior ... are equally easy to program for a ...
... The Finnpipette BioControl is a ... technology. A complete liquid handling system ... twelve interchangeable tip cone modules. All ... tip cone modules fit one handle. ...
Medicine Products: